GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Silence Therapeutics PLC (OTCPK:SLNCF) » Definitions » Book Value per Share

Silence Therapeutics (Silence Therapeutics) Book Value per Share : $1.13 (As of Mar. 2024)


View and export this data going back to 2007. Start your Free Trial

What is Silence Therapeutics Book Value per Share?

Silence Therapeutics's book value per share for the quarter that ended in Mar. 2024 was $1.13.

During the past 12 months, Silence Therapeutics's average Book Value Per Share Growth Rate was 505.90% per year. During the past 3 years, the average Book Value Per Share Growth Rate was 7.60% per year. During the past 5 years, the average Book Value Per Share Growth Rate was -19.30% per year. During the past 10 years, the average Book Value Per Share Growth Rate was -20.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.

During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Silence Therapeutics was 24.10% per year. The lowest was -51.50% per year. And the median was -12.80% per year.

Silence Therapeutics's current price is $7.60. Its book value per share for the quarter that ended in Mar. 2024 was $1.13. Hence, today's PB Ratio of Silence Therapeutics is 6.74.

During the past 13 years, the highest P/B Ratio of Silence Therapeutics was 114.41. The lowest was 3.32. And the median was 13.44.


Silence Therapeutics Book Value per Share Historical Data

The historical data trend for Silence Therapeutics's Book Value per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Silence Therapeutics Book Value per Share Chart

Silence Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Book Value per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.37 0.15 0.13 0.25 0.18

Silence Therapeutics Quarterly Data
Jun18 Dec18 Jun19 Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Book Value per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.19 0.14 0.21 0.18 1.13

Competitive Comparison of Silence Therapeutics's Book Value per Share

For the Biotechnology subindustry, Silence Therapeutics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Silence Therapeutics's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Silence Therapeutics's PB Ratio distribution charts can be found below:

* The bar in red indicates where Silence Therapeutics's PB Ratio falls into.



Silence Therapeutics Book Value per Share Calculation

Silence Therapeutics's Book Value Per Share for the fiscal year that ended in Dec. 2023 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(21.58-0.00)/118.85
=0.18

Silence Therapeutics's Book Value Per Share for the quarter that ended in Mar. 2024 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(157.44-0.00)/139.73
=1.13

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theoretically it is what the shareholders will receive if the company is liquidated. Total Stockholders Equity is a balance sheet item and equal to Total Assets less Total Liabilities of the company.

Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.


Silence Therapeutics  (OTCPK:SLNCF) Book Value per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.


Silence Therapeutics Book Value per Share Related Terms

Thank you for viewing the detailed overview of Silence Therapeutics's Book Value per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Silence Therapeutics (Silence Therapeutics) Business Description

Traded in Other Exchanges
Address
72 Hammersmith Road, London, GBR, W14 8TH
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid. its pipeline products are; SLN360 therapy designed to temporarily block a specific gene's message that would otherwise trigger an unwanted effect. By silencing the LPA gene, the levels of Lp(a) are lowered, which in turn is expected to lower the risk of heart diseases, heart attacks, and strokes, and SLN124 therapy aims to temporarily silence TMPRSS6, a gene that prevents the liver from producing a particular hormone that controls iron levels in the body hepcidin. As hepcidin increases, iron levels in the blood are expected to decrease, which may increase the production of healthy red blood cells, thereby reducing anemia.